People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.
The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.
The user "Dame2Miami" shared their 8-month progress using finasteride and minoxidil for hair loss. Other users commented on their impressive gains and expressed support.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
A 22-year-old is experiencing diffuse hair thinning all over the head, losing about 300 long hairs daily, despite having good genetics and vitamin levels. They are seeking advice on whether this pattern is normal and considering consulting a dermatologist.
A 28-year-old male with a family history of baldness is deciding whether to start finasteride now or wait for visible hair changes. He is considering starting finasteride immediately to proactively address potential hair loss.
A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.
Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
An 18-year-old noticed hair thinning at 17, started finasteride 5 months ago, and saw shedding stop but no regrowth. They suspect male pattern baldness due to family history and are concerned about thinning on the back and sides, possibly due to inflammation.
Vitamin D deficiency might cause hair loss at the temples. The user has a vitamin D level of 9ng and is experiencing hair loss in that area, resembling a Norwood scale 1 (NW1) pattern.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.
The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.
The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.
The user shared their 8-week hair regrowth progress using 0.5mg dutasteride, twice-daily topical minoxidil, and weekly 1.5mm microneedling. They noted visible improvement, though some users suggested reducing microneedling depth to avoid potential scalp damage.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.
A user is considering a hair transplant in a "mohawk" pattern with scalp micropigmentation (SMP) on the sides and back, questioning its feasibility and appearance. Others discuss donor region quality, potential scarring, and alternative treatments like dutasteride and RU58841.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The user shared progress pictures showing crown recovery after 8 months of using 1mg finasteride, 2mg minoxidil, and 2% ketoconazole shampoo. They noted significant hair texture changes and are hopeful for temple recovery.
A 42-year-old male has reached a plateau in hair regrowth after 8 months using Dutasteride, Minoxidil, a dermaroller, and Ketoconazole. Suggestions include continuing treatment, considering a hair transplant, and improving nutrition.
A user shared an 8-month hair loss treatment progress using daily saw palmetto and biotin capsules, weekly dermarolling, and a scalp lotion mix of castor, jojoba, and rosemary oils, avoiding finasteride and minoxidil due to side effects and cost. The user reported encouraging progress with slight hairline improvement and better crown area, attributing most success to dermarolling.
The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.
Treatments for hair loss, including the effectiveness and safety of Pyrilutamide compared to RU58841; experiences using both medications with varying results; and recommendations to try Pyrilutamide instead of RU58841.
Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.